Cargando…

Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy

Extensive biomarker discoveries for DMD have occurred in the past 7 years, and a vast array of these biomarkers were confirmed in independent cohorts and across different laboratories. In these previous studies, glucocorticoids and age were two major confounding variables. In this new study, using S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hathout, Yetrib, Liang, Chen, Ogundele, Michael, Xu, Ganggang, Tawalbeh, Shefa M., Dang, Utkarsh J, Hoffman, Eric P., Gordish-Dressman, Heather, Conklin, Laurie S., van den Anker, John N., Clemens, Paula R., Mah, Jean K., Henricson, Erik, McDonald, Craig
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704115/ https://www.ncbi.nlm.nih.gov/pubmed/31434957 http://dx.doi.org/10.1038/s41598-019-48548-9

Ejemplares similares

Comparison of Serum Pharmacodynamic Biomarkers in Prednisone-Versus Deflazacort-Treated Duchenne Muscular Dystrophy Boys
por: Tawalbeh, Shefa, et al.
Publicado: (2020)

Serum biomarkers associated with baseline clinical severity in young steroid-naïve Duchenne muscular dystrophy boys
por: Dang, Utkarsh J, et al.
Publicado: (2020)

Tandem Mass Tag-Based Serum Proteome Profiling for Biomarker Discovery in Young Duchenne Muscular Dystrophy Boys
por: Alayi, Tchilabalo D., et al.
Publicado: (2020)

Validation of Chemokine Biomarkers in Duchenne Muscular Dystrophy
por: Ogundele, Michael, et al.
Publicado: (2021)

Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy
por: Hathout, Yetrib, et al.
Publicado: (2015)

Modeling Early Heterogeneous Rates of Progression in Boys with Duchenne Muscular Dystrophy
por: Fang, Yuan, et al.
Publicado: (2023)

Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study
por: Boca, Simina M., et al.
Publicado: (2016)

Clinical utility of serum biomarkers in Duchenne muscular dystrophy
por: Hathout, Yetrib, et al.
Publicado: (2016)

Correction: Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study
por: Boca, Simina M., et al.
Publicado: (2016)

Proteomic profiling of glucocorticoid-exposed myogenic cells: Time series assessment of protein translocation and transcription of inactive mRNAs
por: Reeves, Erica KM, et al.
Publicado: (2009)

Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease
por: Heier, Christopher R, et al.
Publicado: (2016)

Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy
por: Khan, Navid, et al.
Publicado: (2019)

Neurodevelopmental Needs in Young Boys with Duchenne Muscular Dystrophy (DMD): Observations from the Cooperative International Neuromuscular Research Group (CINRG) DMD Natural History Study (DNHS).
por: Thangarajh, Mathula, et al.
Publicado: (2018)

Suitability of external controls for drug evaluation in Duchenne muscular dystrophy
por: Goemans, Nathalie, et al.
Publicado: (2020)

Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function
por: Hoffman, Eric P., et al.
Publicado: (2019)

Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy
por: Hogarth, Marshall W., et al.
Publicado: (2017)

Duchenne Regulatory Science Consortium Meeting on Disease Progression Modeling for Duchenne Muscular Dystrophy
por: Larkindale, Jane, et al.
Publicado: (2017)

Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study
por: Smith, Edward C., et al.
Publicado: (2020)

Effect of TNF-α on human ARPE-19-secreted proteins
por: An, Eunkyung, et al.
Publicado: (2008)

Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children
por: Hathout, Yetrib, et al.
Publicado: (2016)

Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis
por: Conklin, Laurie S., et al.
Publicado: (2018)

Duchenne Muscular Dystrophy from Brain to Muscle: The Role of Brain Dystrophin Isoforms in Motor Functions
por: Wijekoon, Nalaka, et al.
Publicado: (2023)

Exon-Skipping in Duchenne Muscular Dystrophy
por: Takeda, Shin’ichi, et al.
Publicado: (2021)

Serum protein biomarkers for juvenile dermatomyositis: a pilot study
por: Tawalbeh, Shefa M., et al.
Publicado: (2020)

Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy
por: Vila, Maria C, et al.
Publicado: (2017)

Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients
por: McDonald, Craig M, et al.
Publicado: (2021)

Genetic modifiers of upper limb function in Duchenne muscular dystrophy
por: Sabbatini, Daniele, et al.
Publicado: (2022)

Genetic modifiers of respiratory function in Duchenne muscular dystrophy
por: Bello, Luca, et al.
Publicado: (2020)

Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy
por: Kao, Kung-Ting, et al.
Publicado: (2019)

Recent advances of glucocorticoids in the treatment of Duchenne muscular dystrophy (Review)
por: Zhang, Tianyuan, et al.
Publicado: (2021)

Current and emerging treatment strategies for Duchenne muscular dystrophy
por: Mah, Jean K
Publicado: (2016)

Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy
por: Clemens, Paula R., et al.
Publicado: (2022)

Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial
por: Mah, Jean K., et al.
Publicado: (2022)

Hypokalemia complicating Duchenne muscular dystrophy.
por: McDonald, B., et al.
Publicado: (1987)

Integrated genomic, proteomic and cognitive assessment in Duchenne Muscular Dystrophy suggest astrocyte centric pathology
por: Wijekoon, Nalaka, et al.
Publicado: (2023)

Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice
por: Ziemba, Michael, et al.
Publicado: (2021)

Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy
por: Biggar, W. Douglas, et al.
Publicado: (2022)

Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA
por: Iff, Joel, et al.
Publicado: (2023)

Percent-Predicted 6-Minute Walk Distance in Duchenne Muscular Dystrophy to Account for Maturational Influences
por: Henricson, Erik, et al.
Publicado: (2012)

Survival in Duchenne muscular dystrophy
por: RALL, SUSANNE, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_lcbdg1c6j4qjbudrem1h9fu39d